1/2/2014 8:33:17 AM
Gilead Sciences Inc. (GILD)’s hepatitis C pill Sovaldi led 27 new U.S. drug approvals in 2013, a “breakthrough” therapy being chased by competitors this year. Gilead’s pill, designed to cut treatment time by about half, was approved under the Food and Drug Administration’s new program that prioritizes reviews of promising medicines. Johnson & Johnson (JNJ) and Pharmacyclics Inc. (PCYC)’s Imbruvica for blood cancer, as well as Roche Holding AG (ROG)’s Gazyva for chronic lymphocytic leukemia, also gained approval under the new designation.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by